Our services 


Decision-making strategy

​IMEC technology can now be used to perform orientation diagnoses for Lyme disease (Borrelia). This rapid, non-invasive technology is suitable for use in the field by technical operators. As such, we are proposing to implement this technology in areas where there is little medical coverage, such as Africa, or even in our medical deserts.

LIMEC approach involves using data analysis and quantitative methods to inform the decision-making process. It relies on statistical models, algorithms, and other analytical techniques to assess diagnosis.

​Partnership

​ We hope to Identify individuals or organizations that can contribute to a partnership to improve new desease detection process with IMEC technology. This include physicians, medical professionals, hospitals, clinics, research institutions, or industry partners. Our partners become co-inventors of the photonic markers that we will highlight through the partnership. Our approach complies fully with patient confidentiality rules. Only patient records are exchanged. The time required to take a complete recording of a patient is 15 minutes, the same as for the witness. We need at least 200 patients. The complete process, assuming the patients are available, requires 500 hours of work over 2 to 3 months.

Substance analysis

​
​LIMEC is a technology that enables measurements to be taken on pharmaceutical specialities, and, surprisingly, on exchanges of photonic energy between the patient's finger and certain substances.
We evaluate these energy exchanges as the patient's affinity for the substance under study. This field of study is still untested, but it promises major advances in the development of personalized medicine.
​Immediate applications concern the choice of the most appropriate drug to treat illnesses such as diabetes.